Lexicon Pharmaceuticals: Strategic Partnerships as a Basis for the Next Valuation Leap?

Cantor Fitzgerald currently rates Lexicon Pharmaceuticals (LXRX) as "Overweight" with a price target of 8 USD. The business model focuses on the marketing of INPEFA as well as profitable partnerships. CEO Lonnel Coats cites cost discipline and collaborations as the basis for future growth. Focus on innovative therapeutics and partnerships Lexicon Pharmaceuticals (LXRX) is dedicated to the discovery and development of medications to treat diseases with unmet medical needs. At the heart of its business model lies the use of genetic insights to...